Mandate

Vinge advises Air Liquide Santé International on the acquisition of NordicInfu Care AB

March 11, 2013

Vinge is advising Air Liquide Santé International in connection with its acquisition of NordicInfu Care AB. Air Liquide Santé International is Europe’s leading and the world’s third largest company within home healthcare and provides treatment for patients with chronic diseases, such as Parkinson, COPD (Chronic Obstructive Pulmonary Disease) and diabetes. Air Liquide Santé International posted revenues of EUR 2.5 billion in 2012 and has 10,000 employees. Air Liquide Santé International is a division within the publicly listed French group Air Liquide.

NordicInfu Care AB is a leading company in the Nordic countries within home infusion therapy for patients with chronic diseases such as Parkinson, PAH (Pulmonary Arterial Hypertension) and diabetes and had a turnover in 2012 of approximately EUR 22 million. Through the acquisition, Air Liquide Santé International expands its home healthcare activities to the Nordic market, where presence up until now has been limited.

The Vinge team advising Air Liquide Santé International includes partner Jesper Ottergren and associate Ida Christiansson. Furthermore, among others, associates Lynn Andersson Wall and Charlotta Cronér (employment law), Rickard Vernet (competition law), Johan Cederblad (regulatory matters) and counsel Maria Schultzberg (tax) have assisted in the transaction.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025